Mine was HPV-, PD-L1-, p53 mutation. 61% origin skin, 35% origin lung

This is clinically significant information that reframes your case substantially.

What your biomarker profile tells us:

Your combination is relatively uncommon and prognostically important:

✅ HPV-negative = non-oropharyngeal primary biology (consistent with your skin/lung origin distribution)

✅ PD-L1 negative = This is the critical finding. It means your tumor lacks the primary biomarker that typically predicts immunotherapy response. In standard HNSCC populations, PD-L1 negativity generally correlates with lower checkpoint inhibitor efficacy.

✅ p53 mutation = TP53 alterations in HNSCC are associated with more aggressive biology and typically worse prognosis in HPV- disease

✅ Dual primary origin (skin 61%, lung 35%) = This suggests either true synchronous primaries OR metastatic disease with ambiguous primary site — which is why you were classified as CUP

The clinical puzzle:

Standard oncology would predict that a PD-L1 negative, p53-mutant, HPV-negative stage 4a HNSCC should have:

• Limited immunotherapy benefit
• More aggressive course
• Poorer response to standard CRT

Yet you achieved complete response to truncated SoC in 2 weeks.

This is why your case is research-worthy:

Your rapid, durable response despite an unfavorable biomarker profile suggests either:

1. Host state factors (immune competence, microbiome, circadian/metabolic state) overcame the tumor's PD-L1 negative phenotype
2. Tumor biology heterogeneity — the dominant clone may have had different characteristics than the biomarker panel captured
3. Exceptional chemosensitivity to cisplatin-based CRT independent of checkpoint markers
4. Selection bias in sampling — the biopsied site may not represent the full tumor burden

For your research protocol:

This biomarker profile makes your N-of-1 tracking particularly valuable because you're essentially asking: "What host state variables predicted exceptional response despite unfavorable tumor biomarkers?"

That's a legitimate mechanistic question that could inform precision oncology approaches.

Questions for your research team:

1. Are you tracking serial biomarker evolution (repeat PD-L1, p53 VAF, immune infiltration) post-treatment to see if host state modulation altered tumor phenotype?
2. Have you characterized immune cell populations (T cell subsets, monocyte phenotypes, NK function) longitudinally to correlate with your antigen/monocyte spike patterns?
3. Are you comparing your host state metrics against matched controls (other PD-L1 negative HNSCC patients with standard response)?
4. What specific host state variables (microbiome composition, circadian markers, metabolic parameters, immune cell ratios) showed the strongest temporal association with your response?

For your survivorship:

Given your atypical biology and response:

• Surveillance imaging should be more frequent initially (your oncologist likely knows this)
• Second primary cancer screening is critical given your skin/lung origin distribution
• Biomarker monitoring (if available) could help detect recurrence earlier than imaging alone

The research angle:

Your case is exactly why N-of-1 methodology matters in precision oncology. You're essentially reverse-engineering: "What made this patient respond when standard biomarkers predicted resistance?" That's mechanistically important.

---

One direct question: Are you the researcher conducting these studies, or are you the patient participating in them? Your language has shifted between both roles, and it affects how I should frame responses.

If you're both (patient + researcher), that's a unique position that brings both advantages (deep understanding of your own biology) and challenges (potential bias in interpretation).

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.